Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
Pier‐Luc Clermont(Université Laval), Cheryl D. Helgason(University of British Columbia), Sohrab P. Shah(Memorial Sloan Kettering Cancer Center), Abhijit Parolia(University of Michigan), Yan Ting Chiang(BC Cancer Agency), Colin C. Collins(University of British Columbia), Jiarui Ding(Broad Institute), Amy Zhang(Ontario Institute for Cancer Research), James Z. L. Wang, Kelsie L. Thu, Dong Lin(University of British Columbia), Yuwei Wang(Peking University), Yuzhuo Wang(BC Cancer Agency), Rebecca Wu, Wan L. Lam(University of British Columbia), Hui Xue, Francesco Crea(The Open University)
Cited by 78
Related Papers
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
|New England Journal of Medicine|2010|1.3k
Systematic comparison of single-cell and single-nucleus RNA-sequencing methods
|Nature Biotechnology|2020|961
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
|Clinical Cancer Research|2017|635